Utilizing both ctDNA and tDNA analysis, the incidence of targetable mutations in this HNSCC cohort was found comparable with other cancers such as breast, ovarian, prostate and pancreatic cancers for which PARP inhibitors are now standard of care. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.